Catalyst Wire Dossier Catalyst Wire Dossier

SARS-CoV-2 recombinant spike protein nanoparticle vaccine (rS), monovalent

SARS-CoV-2 recombinant spike protein nanoparticle vaccine · Novavax, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SARS-CoV-2 recombinant spike protein nanoparticle vaccine (rS), monovalent, covering 2024-12-13 to 2024-12-13. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines [Phase 2, Phase 3]

See pricing